Key Events This Week
23 Mar: Stock hits 52-week low at Rs.1,922.45 amid sector and market downturn
24 Mar: Strong rebound with 3.37% gain supported by market recovery
25 Mar: Continued upward momentum with 1.66% rise and surge in delivery volumes
27 Mar: Sharp open interest surge in derivatives amid bullish positioning, stock closes at Rs.2,040.25 (+0.99%)
23 March: Stock Hits 52-Week Low Amid Market and Sector Weakness
On 23 March 2026, Mankind Pharma’s stock plunged to a 52-week low of Rs.1,922.45, down 3.87% from the previous close. This decline coincided with a sharp fall in the Sensex, which dropped 3.13% to 32,377.87, reflecting a broad market sell-off. The Pharmaceuticals & Biotechnology sector also declined by 3.09%, underscoring sector-wide pressures. The stock’s three-day losing streak culminated in a cumulative 7.73% drop, driven by concerns over valuation and profit declines, as well as technical indicators signalling bearish momentum. The stock traded below all major moving averages, indicating sustained downward pressure.
24 March: Market Recovery Spurs 3.37% Rebound in Stock Price
Following the sharp decline, Mankind Pharma rebounded strongly on 24 March, gaining 3.37% to close at Rs.1,987.25. This recovery was supported by a broader market rally, with the Sensex rising 1.95% to 33,009.57. The stock’s volume increased to 22,875 shares, reflecting renewed investor interest. The sector also showed signs of stabilisation, helping the stock regain some lost ground. This day marked the beginning of a three-day winning streak for the stock, signalling a shift in short-term sentiment.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
25 March: Continued Gains Supported by Strong Delivery Volumes
The positive momentum extended into 25 March, with the stock rising 1.66% to Rs.2,020.25. This advance was accompanied by a significant surge in delivery volumes, reaching 9.48 lakh shares, a 111.52% increase over the five-day average. The Sensex also gained 1.93% to 33,645.89, reflecting a broadly bullish market mood. The stock’s three-day winning streak delivered a cumulative return of 5.49%, signalling improving investor confidence despite the stock remaining below key longer-term moving averages.
27 March: Sharp Open Interest Surge Indicates Bullish Market Positioning
On 27 March, Mankind Pharma’s derivatives market saw a sharp increase in open interest, rising by 11.35% to 26,008 contracts. This surge, alongside a traded volume of 17,334 contracts, suggests fresh bullish positions being established. The futures segment alone accounted for approximately ₹40,554 lakhs in value, with options contributing ₹4,027 crore, highlighting robust market participation. The stock closed at Rs.2,040.25, up 0.99%, outperforming the Sensex which declined 2.11% that day. Despite this short-term strength, the stock remains below its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that longer-term resistance levels persist.
Is Mankind Pharma Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Daily Price Comparison: Mankind Pharma vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-23 | Rs.1,922.45 | -3.87% | 32,377.87 | -3.13% |
| 2026-03-24 | Rs.1,987.25 | +3.37% | 33,009.57 | +1.95% |
| 2026-03-25 | Rs.2,020.25 | +1.66% | 33,645.89 | +1.93% |
| 2026-03-27 | Rs.2,040.25 | +0.99% | 32,935.19 | -2.11% |
Key Takeaways
Positive Signals: Mankind Pharma demonstrated resilience by recovering from a 52-week low and delivering a 6.13% gain from the week’s low to close at its highest price of Rs.2,040.25. The surge in derivatives open interest and strong delivery volumes indicate growing investor interest and potential for further short-term momentum. The stock’s outperformance relative to the Sensex, which declined 7.59% over the same period, highlights its relative strength amid market volatility.
Cautionary Notes: Despite recent gains, the stock remains below key longer-term moving averages (20-day, 50-day, 100-day, 200-day), signalling that resistance levels have yet to be decisively breached. The mojo grade remains at Sell with a score of 38.0, reflecting concerns over valuation and near-term fundamentals. Investors should be mindful of these technical and fundamental headwinds when assessing the stock’s outlook.
Conclusion
Mankind Pharma Ltd’s week was characterised by a sharp initial decline to a 52-week low, followed by a steady recovery supported by improving market sentiment and increased derivatives activity. The stock’s 2.03% weekly gain and outperformance against the Sensex underscore its ability to navigate a challenging sector and market environment. However, the persistence of technical resistance and a cautious mojo rating suggest that the stock’s path forward remains uncertain. Monitoring open interest trends alongside price action will be key to understanding whether the current bullish positioning can translate into a sustained uptrend.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
